Skip to main content
Livermore
Livermore
ZHEN

Great Point Partners LLC

SEC CIK
0001281446
Latest filing
Aug 14, 2026

Holdings in Q1 2025

Holdings as of Mar 31, 2025, filed May 15, 2025. Long positions only; changes compare share counts with Q4 2024.

Institution overview
Positions
31
+5 vs. Q4 2024
Portfolio value
$184.0M
−$28.2M (−13.3%) vs. Q4 2024
Filed
May 15, 2025
SEC
Holdings of Great Point Partners LLC in Q1 2025
SecurityClassSharesValue% of portfolioShare changeActionHistory
CYTKCytokinetics IncCOM NEW370,000$14.9M8.1%+10,000+2.8%AddedHistory
KALVKalVista Pharmaceuticals, Inc.COM1,014,367$11.7M6.4%−772,636−43.2%ReducedHistory
EOLSEvolus, Inc.COM944,743$11.4M6.2%+49,219+5.5%AddedHistory
ABVXAbivax S.A.SPONSORED ADS1,638,111$10.2M5.6%−10,412−0.6%ReducedHistory
VRDNViridian Therapeutics, Inc.COM750,000$10.1M5.5%00.0%UnchangedHistory
MRUSMerus N.V.COM237,156$9.98M5.4%+79,064+50.0%AddedHistory
AKBAAkebia Therapeutics, Inc.COM4,973,840$9.55M5.2%+4,973,840NewHistory
XENEXenon Pharmaceuticals Inc.COM245,272$8.23M4.5%00.0%UnchangedHistory
ASNDAscendis Pharma A/SSPONSORED ADR50,000$7.79M4.2%+50,000NewHistory
DVAXDynavax Technologies CorpCOM NEW595,879$7.73M4.2%−264,121−30.7%ReducedHistory
IONSIonis Pharmaceuticals IncCOM250,000$7.54M4.1%−255,007−50.5%ReducedHistory
AMLXAmylyx Pharmaceuticals, Inc.COM1,811,996$6.41M3.5%+1,811,996NewHistory
IMVTImmunovant, Inc.COM375,000$6.41M3.5%+375,000NewHistory
UNCYUnicycive Therapeutics, Inc.COM10,980,000$6.31M3.4%00.0%UnchangedHistory
NGNENeurogene Inc.COM470,964$5.51M3.0%+28,203+6.4%AddedHistory
DNTHDianthus Therapeutics, Inc.COM275,000$4.99M2.7%00.0%UnchangedHistory
LEGNLegend Biotech CorpSPONSORED ADS138,240$4.69M2.5%+138,240NewHistory
PCVXVaxcyte, Inc.COM115,517$4.36M2.4%+115,517NewHistory
AUTLAutolus Therapeutics plcSPON ADS2,728,910$4.23M2.3%−280,482−9.3%ReducedHistory
BBOTBridgeBio Oncology Therapeutics, Inc.CL A ORD SHS373,833$4.22M2.3%−126,167−25.2%ReducedHistory
ZURAZura Bio LtdCLASS A ORD SHS3,170,194$4.09M2.2%00.0%UnchangedHistory
BEAMBeam Therapeutics Inc.COM175,562$3.43M1.9%+175,562NewHistory
ACLXArcellx, Inc.COMMON STOCK45,000$2.95M1.6%+45,000NewHistory
MREOMereo BioPharma Group plcSPON ADS1,275,000$2.87M1.6%+125,000+10.9%AddedHistory
CNTXContext Therapeutics Inc.COM4,683,711$2.87M1.6%00.0%UnchangedHistory
RZLTRezolute, Inc.COM NEW833,042$2.42M1.3%+211,148+34.0%AddedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS149,702$2.15M1.2%+149,702NewHistory
VYGRVoyager Therapeutics, Inc.COM626,275$2.12M1.2%−200,476−24.2%ReducedHistory
PMNProMIS Neurosciences Inc.COM2,645,128$1.84M1.0%00.0%UnchangedHistory
UPBUpstream Bio, Inc.COM300,000$1.84M1.0%00.0%UnchangedHistory
PLRXPliant Therapeutics, Inc.COM850,000$1.15M0.6%−205,000−19.4%ReducedHistory

Options (1)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Great Point Partners LLC in Q1 2025
SecurityClassPutsCalls
SMMTSummit Therapeutics Inc.COM$4.82M–

Sold out since Q4 2024 (4)

Positions held at the end of Q4 2024 that are gone from this filing.

Positions of Great Point Partners LLC sold out since Q4 2024
SecurityClassShares in Q4 2024Value in Q4 2024% of portfolio in Q4 2024History
JSPRJasper Therapeutics, Inc.COM NEW322,380$6.89M3.2%History
ORKAOruka Therapeutics, Inc.COM228,803$4.44M2.1%History
OPTNOptiNose, Inc.COM NEW370,269$2.47M1.2%History
URGNUroGen Pharma Ltd.COM187,843$2.00M0.9%History